

10/585625

AP20 Rec'd PCT/PTO 11 JUL 2006

CASE 33651-US-PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

ROBIN ALEC FAIRHURST

INTERNATIONAL APPLICATION NO: PCT/EP2005/0012421

FILED: 8 FEBRUARY 2005

U.S. APPLICATION NO: Not yet known

35 USC §371 DATE:

FOR: COMBINATION OF BENZOTHIAZOL-2-ONE BETA2  
ADRENOCEPTOR AGONISTS AND CORTICOSTEROIDS FOR THE  
TREATMENT OF RESPIRATORY DISEASES

**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2005/0012421, copies are not enclosed herewith.


10/585625

AP20 Rec'd PCT/PTO 11 JUL 2006

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-2614

  
Gregory C. Houghton  
Attorney for Applicant  
Reg. No. 47,666

Date: 7/11/06

ATTY. DOCKET NO.  
33651-US-PCT  
APPLICATION NO.  
Not Yet Known  
APPLICANT  
Robin Alec FAIRHURST  
FILING DATE  
Herewith

10/585625

Group

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AP20 Rec'd PCT/PTO 11 JUL 2006

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	99/09018	2/25/99	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	2004/016601	2/26/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Suzuki et al., "The effects of S1319, a novel marine sponge-derived beta.2-adrenoceptor agonist, on IgE-mediated activation of human cultured mast cells," Inflammation Research, Birkhaeuser Verlag, Basel, CH, Vol. 49, No. 2, pp. 86-94 (2000)
	AS	Suzuki et al., "S1319: a novel beta2-adrenoceptor agonist from a marine sponge Dysidea sp.," Bioorganic & Medicinal Chemistry Letters, Vol. 9, No. 10, pp. 1361-1364 (1999)
	AT	McGavin et al., "Inhaled Budesonide/Formoterol Combination," Drugs, Adis International Ltd., AT, Vol. 61, No. 1, p. 71-78 (2001)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
33651-US-PCT  
APPLICATION NO.  
Not Yet Known

**10/585625**

**AP20060711** **11 JUL 2006**  
FILING DATE  
Herewith

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM						<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	Palmovist et al., "Onset of Bronchodilation of Budesonide/Formoterol Vs. Salmeterol/Fluticasone in Single Inhalers," Pulmonary Pharmacology and Therapeutics, Vol. 14, No. 1, pp. 29-34 (2001)
	BS	O'Connor et al.; "Dose-Ranging Study of Mometasone Furoate Dry Power Inhaler in the Treatment of Moderate Persistent Asthma Using Fluticasone Propionate as an Active Comparator," Annals of Allergy, Asthma & Immunology, Vol. 86, No. 4, pp. 397-404 (2001)
	BT	

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.